Can Men Take Ozempic for Weight Loss? Clinical Evidence

Last reviewed: June 3, 2026

Last updated: June 3, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Men can use GLP-1 receptor agonists like Ozempic off-label for weight loss, though the medication carries an FDA indication for type 2 diabetes. Clinical trials show men experience similar weight reduction and cardiometabolic benefits as women, with average weight losses of 15-22% in structured programs.

Understanding whether a GLP-1 approach fits your health profile requires more than dose adjustments—it requires clarity on how your individual genetics, metabolic biomarkers, and cardiovascular risk factors interact with medication options. PlexusDx emphasizes precision wellness by pairing clinical evidence with personalized genetic insights to support informed conversations with your provider.

Why Men May Respond Differently to GLP-1 Medications

Research indicates men and women show comparable efficacy with GLP-1 receptor agonists for weight loss and glycemic control, yet metabolic starting points often differ. Men typically carry more visceral adiposity (deep abdominal fat), which carries higher cardiometabolic risk, making early intervention potentially more impactful for cardiovascular outcomes.

Hormone profiles also influence medication tolerability and response. Testosterone levels, which naturally decline with age in men, interact with appetite regulation pathways that GLP-1 medications target. Understanding these baseline differences helps providers tailor therapy duration, dose escalation, and monitoring strategies for individual men.

Clinical Evidence: Safety and Efficacy in Male Populations

Multiple randomized controlled trials examined GLP-1 receptor agonists in predominantly or exclusively male cohorts. The SUSTAIN and SELECT trials both included significant male enrollment and demonstrated sustained weight loss, improved blood pressure, and reduced cardiovascular events across gender groups.

Clinical Parameter	Men's Data from Major Trials
Average Weight Loss (24-68 weeks)	15-22% body weight reduction with GLP-1 therapy
Cardiovascular Benefit	Reduced major adverse events; blood pressure improvements sustained
Gastrointestinal Side Effects	Nausea, vomiting most common; typically mild-to-moderate and decrease over 8-12 weeks
Adherence Rates	~75-80% completion in weight-loss programs; men report higher early dropout if GI side effects severe
Metabolic Marker Improvement	HbA1c reduction 1-1.5%, triglycerides improve 20-30%, LDL stable or improved

Genetic Predispositions and Personalized Response Pathways

Not all men respond identically to GLP-1 medications. Genetic variants in the GLP1R gene, MC4R gene, and other appetite-regulation pathways influence baseline hunger signaling, satiety response, and medication tolerability. Some men may achieve optimal weight loss at lower doses, while others require higher escalation.

The FTO rs9939609 variant, associated with increased appetite drive, may predict which men benefit most from GLP-1 therapy's appetite-suppression mechanism. Similarly, GIPR variants influence incretin sensitivity. These predispositions do not determine exact outcomes but may help inform initial dose strategies and provider expectations.

Who Should Consider This Approach: Safety, Eligibility, and Provider Guidance

Men with a BMI ≥27 and at least one weight-related comorbidity (hypertension, prediabetes, cardiovascular disease) or those with BMI ≥30 are generally considered candidates for GLP-1 therapy. However, personal or family history of thyroid cancer, pancreatitis, or medullary thyroid carcinoma contraindicates use. A qualified healthcare provider must evaluate contraindications and medication interactions.

Before starting, men should understand that GLP-1 medications require gradual dose escalation, ongoing monitoring for side effects, and commitment to behavior change. Genetic testing can support this conversation by revealing predispositions in appetite and metabolic pathways, helping providers set realistic timelines and identify which men may tolerate lower doses effectively.

How PlexusDx Supports a More Personalized Approach

PlexusDx's approach to GLP-1 therapy for men incorporates the Precision Peptide Genetic Test, which evaluates predispositions in key pathways: GLP1R (rs6923761), GIPR (rs1800437), MC4R (rs17782313), and FTO (rs9939609). These variants may help provide context for how your appetite-regulation and metabolic systems respond to GLP-1 mechanisms, supporting a more informed conversation with your provider about medication selection and dose strategy.

The genetic test reveals predispositions—not exact medication response or guaranteed outcomes. A man with favorable GLP1R variants may show robust appetite suppression at standard doses, while another may require higher escalation or experience slower satiety benefits. This information, interpreted with your provider, clarifies whether compounded GLP-1 options align with your genetic and metabolic profile.

PlexusDx offers compounded semaglutide and tirzepatide injections from licensed 503A pharmacies, with flat pricing across commitment tiers starting at $149/month for compounded semaglutide injection. Pricing does not increase with dose escalation—your dose may go up, but your price won't. Pairing genetic insights with transparent medication access empowers men to make personalized, evidence-based treatment decisions.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.